The Australian Chapter of BDSRA

“We are pleased about the progress that BioMarin is making in developing a treatment for CLN2 disorder,” said Margie Frazier, Ph.D., Executive Director, Batten Disease Support and Research Association. “This is a notable moment, which holds promise for the children and families who are affected by this disease.”

Read More here:

 http://www.streetinsider.com/Corporate+News/BioMarin+(BMRN)+Says+Data+from+Phase+12+190+Study+Shows+Stabilization+of+Disease/10157053.html